Artivion SVP Stanton sells $442k in company stock

Artivion, INC. (NYSE:AORT) Senior Vice President, Clinical & MD Affair, Marshall S. Stanton, sold 15,000 shares of company stock on June 17, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $29.50, for a total transaction value of $442500.

The sales involved 13,764 shares and 1236 shares. Following the transactions, Stanton directly owns 64,200 shares of Artivion, INC.

The sale was executed under a pre-arranged 10b5-1 trading plan adopted on March 14, 2025.

In other recent news, Artivion Inc. reported first-quarter 2025 earnings that exceeded Wall Street expectations, with sales reaching $99 million against a consensus of $95 million. This growth was largely driven by the early success of the AMDS product, contributing to a 19% year-over-year increase in the aortic stent graft business. However, the company’s tissue processing business experienced a 23% decline due to supply chain issues from a previous cybersecurity incident. Analysts from JMP Securities and Stifel maintained positive ratings for Artivion, with price targets set at $33 and $30, respectively, highlighting continued optimism in the company’s growth prospects.

Additionally, Artivion’s shareholders approved executive compensation and additional equity funding at the recent annual meeting. The company also announced a private deal to exchange approximately $95 million of its convertible senior notes for common stock, aiming to manage its debt effectively. Canaccord Genuity initiated coverage of Artivion with a buy rating, citing strategic investments in aortic arch repair as a key factor. The launch of new products like the Ascyrus AMDS and anticipated approvals for Endospan’s NEXUS and JOTEC’s Arcevo are expected to drive future growth. These developments reflect Artivion’s strategic focus on expanding its market presence and addressing supply chain challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.